Dry eye disease (DED), keratoconjunctivitis sicca or dysfunctional tear syndrome, is the most
prevalent ophthalmic disease which affects a substantial segment of people worldwide with …

Dry eye disease (DED) is a frequently observed eye complaint, which has recently attracted
considerable research interest. Conventional therapy for DED involves the use of artificial …

Dry eye disease (DED) impacts≈ 30% of the world's population and causes serious ocular
discomfort and even visual impairment. Inflammation is one core cause of the DED vicious …

Dry eye disease (DED) is one of the most common ocular surface disorders characterised by
a deficiency in quality and/or quantity of the tear fluid. Due to its multifactorial nature …

Dry eye syndrome (DES) is multifactorial and likely to be a cause of concern more so than
ever given the rapid pace of modernization, which is directly associated with many of the …

Importance Dry eye disease (DED) is a common public health problem with significant
impact on vision-related quality of life and well-being of patients. Medications with rapid …

To design an ocular drug delivery system is challenging due to the limited space of the
ocular surface and high sensitivity of the cornea. Here, we developed a lacrimal duct drug …

Tissue‐specific delivery of oligonucleotide therapeutics beyond the liver remains a key
challenge in nucleic acid drug development. To address this issue, exploiting exosomes as …

A biomarker is a “characteristic that is measured as an indicator of normal biological
processes, pathogenic processes, or responses to an exposure or intervention, including …

Introduction Early initiation of anti-inflammatory therapies is recommended for dry eye
disease (DED) to break the vicious cycle of pathophysiology. However, there is limited …